2,360 Shares in Healthequity Inc (HQY) Acquired by Zions Bancorporation

Zions Bancorporation purchased a new position in shares of Healthequity Inc (NASDAQ:HQY) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,360 shares of the company’s stock, valued at approximately $119,000.

Several other institutional investors also recently added to or reduced their stakes in HQY. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Healthequity by 105.8% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,544 shares of the company’s stock worth $127,000 after acquiring an additional 1,308 shares in the last quarter. Riverhead Capital Management LLC raised its position in Healthequity by 75.3% in the second quarter. Riverhead Capital Management LLC now owns 2,629 shares of the company’s stock worth $131,000 after acquiring an additional 1,129 shares in the last quarter. Oppenheimer Asset Management Inc. raised its position in Healthequity by 7.7% in the second quarter. Oppenheimer Asset Management Inc. now owns 2,686 shares of the company’s stock worth $134,000 after acquiring an additional 191 shares in the last quarter. Fortaleza Asset Management Inc. purchased a new position in Healthequity in the second quarter worth $138,000. Finally, D.A. Davidson & CO. raised its position in Healthequity by 15.2% in the second quarter. D.A. Davidson & CO. now owns 3,326 shares of the company’s stock worth $165,000 after acquiring an additional 439 shares in the last quarter. Institutional investors and hedge funds own 98.60% of the company’s stock.

Healthequity Inc (NASDAQ HQY) opened at $44.80 on Friday. Healthequity Inc has a 52-week low of $37.62 and a 52-week high of $55.31. The firm has a market capitalization of $2,690.00, a price-to-earnings ratio of 62.51, a PEG ratio of 1.81 and a beta of 1.74.

Healthequity (NASDAQ:HQY) last announced its quarterly earnings results on Tuesday, December 5th. The company reported $0.17 earnings per share for the quarter, beating analysts’ consensus estimates of $0.13 by $0.04. Healthequity had a return on equity of 14.47% and a net margin of 21.08%. The business had revenue of $56.80 million during the quarter, compared to analysts’ expectations of $55.27 million. During the same quarter last year, the business posted $0.10 earnings per share. The business’s revenue for the quarter was up 31.0% on a year-over-year basis. analysts forecast that Healthequity Inc will post 0.71 earnings per share for the current fiscal year.

In related news, Director Frank Medici sold 419,504 shares of the stock in a transaction on Monday, November 6th. The stock was sold at an average price of $52.97, for a total transaction of $22,221,126.88. Following the sale, the director now owns 6,381 shares of the company’s stock, valued at $338,001.57. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Darcy G. Mott sold 9,500 shares of the stock in a transaction on Wednesday, September 20th. The shares were sold at an average price of $46.79, for a total value of $444,505.00. Following the sale, the vice president now directly owns 87,500 shares in the company, valued at approximately $4,094,125. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,761,117 shares of company stock valued at $91,904,676. Company insiders own 29.00% of the company’s stock.

Several research firms have issued reports on HQY. BidaskClub upgraded Healthequity from a “sell” rating to a “hold” rating in a research report on Tuesday, November 7th. Zacks Investment Research upgraded Healthequity from a “hold” rating to a “buy” rating and set a $58.00 price objective for the company in a research report on Wednesday, October 11th. Robert W. Baird reiterated a “hold” rating on shares of Healthequity in a research report on Thursday, September 21st. Cantor Fitzgerald reiterated a “buy” rating and issued a $56.00 price objective on shares of Healthequity in a research report on Tuesday, December 5th. Finally, Chardan Capital increased their price objective on Healthequity from $58.00 to $62.00 and gave the stock a “buy” rating in a research report on Wednesday, December 6th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $58.33.

COPYRIGHT VIOLATION WARNING: “2,360 Shares in Healthequity Inc (HQY) Acquired by Zions Bancorporation” was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://sportsperspectives.com/2017/12/15/2360-shares-in-healthequity-inc-hqy-acquired-by-zions-bancorporation.html.

About Healthequity

HealthEquity, Inc provides a range of solutions for managing healthcare accounts (Health Savings Accounts (HSAs), Health Reimbursement Arrangements (HRAs) and Flexible Spending Accounts (FSAs)) for health plans, insurance companies and third-party administrators. The Company is engaged in technology-enabled services platforms that allow consumers to make healthcare saving and spending decisions.

Want to see what other hedge funds are holding HQY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Healthequity Inc (NASDAQ:HQY).

Institutional Ownership by Quarter for Healthequity (NASDAQ:HQY)

Receive News & Ratings for Healthequity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply